The two parties will work together to conduct genomic research on lung cancer and liver cancer, two of the most common cancers in Asia. Lung cancer is one of the most common cancers for males and causes about 1.3 million deaths globally per year. The incidence of lung cancer has risen dramatically for both males and females in Asia in past decades. Liver cancer is the sixth most commonly diagnosed cancer and the third leading cause of cancer death. Hepatocellular carcinoma (HCC), the most common type of liver cancer, causes nearly 700,000 deaths worldwide annually, half of which occur in China.
BGI and ACRG will conduct the lung and liver cancer studies at the genomic level. ACRG will provide samples of lung and liver cancer tissues, and BGI will sequence these samples on its large-scale next-generation sequencing platforms, produce high-quality data output and provide bioinformatics analysis.
"The collaboration will accelerate the establishment of a pharmacogenomic database for Asian lung and liver cancers," said Dr. Mao Mao, President of ACRG. "Through this collaboration and the subsequent sharing of information with the broader scientific community, we are hoping to increase our knowledge of these two common cancers in Asia, and to accelerate the development of new diagnostic methods and therapies."
"We are very excited about this new partnership with ACRG. Given BGI's expertise in genomics research and ACRG's advances in cancer studies, I believe this partnership will accelerate cancer research, from understanding the basic mechanism to developing effective treatments for cancer," said Professor Huanming Yang, Chairman of BGI. "It's our first time applying comprehensive solutions to cancer research, and we believe the study will bring new perspectives for researchers that could facilitate biotechnology and pharmaceutical research in the future." he added.
Provided by BGI Shenzhen
This Phys.org Science News Wire page contains a press release issued by an organization mentioned above and is provided to you “as is” with little or no review from Phys.Org staff.